<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>Expert Review of Ophthalmology via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Expert Review of Ophthalmology' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Expert+Review+of+Ophthalmology&t=Expert+Review+of+Ophthalmology&s=Search&f=source]]></link>
        <lastBuildDate>Fri, 02 Apr 2010 15:01:45 +0100</lastBuildDate>
        <item>
            <title>Anterior-segment imaging for assessment of glaucoma.</title>
            <link>http://www.medworm.com/index.php?rid=3395862&amp;cid=s_37211_30_f&amp;fid=37211&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20305726%26dopt%3DAbstract</link>
            <description>This article summarizes the physics, technology and clinical application of ultrasound biomicroscopy (UBM) and optical coherence tomography (OCT) for assessment of the anterior segment in glaucoma. UBM systems use frequencies ranging from approximately 35 to 80 MHz, as compared with typical 10-MHz systems used for general-purpose ophthalmic imaging. OCT systems use low-coherence, near-infrared light to provide detailed images of anterior segment structures at resolutions exceeding that of UBM. Both technologies allow visualization of the iridocorneal angle and, thus, can contribute to the diagnosis and management of glaucoma. OCT systems are advantageous, being noncontact proceedures and providing finer resolution than UBM, but UBM systems are superior for the visualization of retroiridal ...</description>
            <author>Expert Review of Ophthalmology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3395862</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3395862</guid>        </item>
        <item>
            <title>Drug delivery to the posterior segment of the eye for pharmacologic therapy.</title>
            <link>http://www.medworm.com/index.php?rid=3395861&amp;cid=s_37211_30_f&amp;fid=37211&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20305803%26dopt%3DAbstract</link>
            <description>This article summarizes recent advances in the research and development of drug delivery methods of the posterior chamber of the eye, with an emphasis on the use of implantable devices as well as micro- and nanoparticles.
    PMID: 20305803 [PubMed - as supplied by publisher] (Source: Expert Review of Ophthalmology)</description>
            <author>Expert Review of Ophthalmology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3395861</comments>
            <pubDate>Mon, 01 Feb 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3395861</guid>        </item>
        <item>
            <title>Vitreous Substitutes.</title>
            <link>http://www.medworm.com/index.php?rid=2314194&amp;cid=s_37211_30_f&amp;fid=37211&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19343097%26dopt%3DAbstract</link>
            <description>Authors: Foster WJ
    Modern vitreoretinal surgery is a young science. While tremendous developments have occurred in instrument design and technique since Machemer first described vitrectomy surgery in 1973[1], the application of advanced materials concepts to the development of intra-ocular compounds is a particularly exciting area of research. To date, the development of vitreous substitutes has played a significant role in enabling the dramatic and progressive improvement in surgical outcome, but perhaps no other area of research has the potential to further improve the treatment of retinal detachment and other retinal disorders. While prior research has focused solely upon the ability of a compound to re-attach the retina, future research should seek to enable the surgeon to inhibit ...</description>
            <author>Expert Review of Ophthalmology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2314194</comments>
            <pubDate>Tue, 01 Apr 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2314194</guid>        </item>
        <item>
            <title>Ocular toxicity of fludarabine: a purine analog.</title>
            <link>http://www.medworm.com/index.php?rid=1557280&amp;cid=s_37211_30_f&amp;fid=37211&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18461151%26dopt%3DAbstract</link>
            <description>Authors: Ding X, Herzlich AA, Bishop R, Tuo J, Chan CC
    The purine analogs, fludarabine and cladribine represent an important class of chemotherapy agents used to treat a broad spectrum of lymphoid malignancies. Their toxicity profiles include dose-limiting myelosuppression, immunosuppression, opportunistic infection and severe neurotoxicity. This review summarizes the neurotoxicity of high- and standard-dose fludarabine, focusing on the clinical and pathological manifestations in the eye. The mechanisms of ocular toxicity are probably multifactorial. With increasing clinical use, an awareness of the neurological and ocular vulnerability, particularly to fludarabine, is important owing to the potential for life- and sight-threatening consequences.
    PMID: 18461151 [PubMed - as supplie...</description>
            <author>Expert Review of Ophthalmology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1557280</comments>
            <pubDate>Fri, 01 Feb 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1557280</guid>        </item>
        <item>
            <title>Unfolding the Therapeutic Potential of Chemical Chaperones for Age-related Macular Degeneration.</title>
            <link>http://www.medworm.com/index.php?rid=1557279&amp;cid=s_37211_30_f&amp;fid=37211&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D18528533%26dopt%3DAbstract</link>
            <description>Authors: Sauer T, Patel M, Chan CC, Tuo J
    SUMMARYRecent studies suggest that pathological processes involved in age-related macular degeneration (AMD) might induce endoplasmic reticulum (ER) stress. Growing evidence demonstrates the ability of chemical chaperones to decrease ER stress and ameliorate ER stress-related disease phenotypes, suggesting that the field of chaperone therapy might hold novel treatments for AMD. In this review, we examine the evidence suggesting a role for ER stress in AMD. Furthermore, we discuss the use of chaperone therapy for the treatment of ER stress-associated diseases, including other neurodegenerative diseases and retinopathies. Finally, we examine strategies for identifying potential chaperone compounds and for experimentally demonstrating chaperone ac...</description>
            <author>Expert Review of Ophthalmology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1557279</comments>
            <pubDate>Fri, 01 Feb 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">1557279</guid>        </item>
        <item>
            <title>Genetic markers and biomarkers for age-related macular degeneration.</title>
            <link>http://www.medworm.com/index.php?rid=1557281&amp;cid=s_37211_30_f&amp;fid=37211&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D17917691%26dopt%3DAbstract</link>
            <description>Authors: Ross RJ, Verma V, Rosenberg KI, Chan CC, Tuo J
    Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness in the USA. Although the treatment of AMD has evolved to include laser photocoagulation, photodynamic therapy, surgical macular translocation and antiangiogenesis agents, treatment options for advanced AMD are limited. Furthermore, the dry form of AMD, albeit less devastating than the wet form, has even fewer viable treatment options. This review summarizes the various biomarkers of AMD and analyzes whether or not they may one day be exploited to determine risks of disease onset, measure progression of disease or even assess the effects of treatment of AMD. Potential biomarkers are important to identify since some might be utilized to re...</description>
            <author>Expert Review of Ophthalmology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1557281</comments>
            <pubDate>Fri, 01 Jun 2007 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1557281</guid>        </item>
    </channel>
</rss>

